INTRODUCTION: : Canada has endorsed the Joint United National Programme on HIV and AIDS global targets to end the acquired immunodeficiency syndrome (AIDS) epidemic, including reducing new human immunodeficiency virus (HIV) infections to zero, by 2030. Given the effectiveness of pre-exposure prophylaxis (PrEP) to prevent new infections, it is important to measure and report on PrEP utilization to help inform planning for HIV prevention programs and policies. METHODS: : Annual estimates of persons using PrEP in Canada were generated for 2014-2018 from IQVIA's geographical prescription monitor dataset. An algorithm was used to distinguish users of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for PrEP versus treatment or post-exposure prophylaxis. We provide the estimated number of people using PrEP in eight Canadian provinces by sex, age group, prescriber specialty and payment type. RESULTS: : The estimated number of PrEP users increased dramatically over the five-year study period, showing a 21-fold increase from 460 in 2014 to 9,657 in 2018. Estimated PrEP prevalence was 416 users per million persons across the eight provinces in 2018. Almost all PrEP users were male. Use increased in both sexes, but increase was greater for males (23-fold) than females (five-fold). Use increased across all provinces, although there were jurisdictional differences in the prevalence of use, age distribution and prescriber types. CONCLUSION: : The PrEP use in Canada increased from 2014 to 2018, demonstrating increased awareness and uptake of its use for preventing HIV transmission. However, there was uneven uptake by age, sex and geography. Since new HIV infections continue to occur in Canada, it will be important to further refine the use of PrEP, as populations at higher risk of HIV infection need to be offered PrEP as part of comprehensive sexual healthcare.
INTRODUCTION: : Canada has endorsed the Joint United National Programme on HIV and AIDS global targets to end the acquired immunodeficiency syndrome (AIDS) epidemic, including reducing new human immunodeficiency virus (HIV) infections to zero, by 2030. Given the effectiveness of pre-exposure prophylaxis (PrEP) to prevent new infections, it is important to measure and report on PrEP utilization to help inform planning for HIV prevention programs and policies. METHODS: : Annual estimates of persons using PrEP in Canada were generated for 2014-2018 from IQVIA's geographical prescription monitor dataset. An algorithm was used to distinguish users of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for PrEP versus treatment or post-exposure prophylaxis. We provide the estimated number of people using PrEP in eight Canadian provinces by sex, age group, prescriber specialty and payment type. RESULTS: : The estimated number of PrEP users increased dramatically over the five-year study period, showing a 21-fold increase from 460 in 2014 to 9,657 in 2018. Estimated PrEP prevalence was 416 users per million persons across the eight provinces in 2018. Almost all PrEP users were male. Use increased in both sexes, but increase was greater for males (23-fold) than females (five-fold). Use increased across all provinces, although there were jurisdictional differences in the prevalence of use, age distribution and prescriber types. CONCLUSION: : The PrEP use in Canada increased from 2014 to 2018, demonstrating increased awareness and uptake of its use for preventing HIV transmission. However, there was uneven uptake by age, sex and geography. Since new HIV infections continue to occur in Canada, it will be important to further refine the use of PrEP, as populations at higher risk of HIV infection need to be offered PrEP as part of comprehensive sexual healthcare.
Authors: Hsiu Wu; Maria C B Mendoza; Ya-Lin A Huang; Tameka Hayes; Dawn K Smith; Karen W Hoover Journal: Clin Infect Dis Date: 2016-10-19 Impact factor: 9.079
Authors: Darrell H S Tan; Mark W Hull; Deborah Yoong; Cécile Tremblay; Patrick O'Byrne; Réjean Thomas; Julie Kille; Jean-Guy Baril; Joseph Cox; Pierre Giguere; Marianne Harris; Christine Hughes; Paul MacPherson; Shannon O'Donnell; Joss Reimer; Ameeta Singh; Lisa Barrett; Isaac Bogoch; Jody Jollimore; Gilles Lambert; Bertrand Lebouche; Gila Metz; Tim Rogers; Stephen Shafran Journal: CMAJ Date: 2017-11-27 Impact factor: 8.262
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Terrance Mosley; Moliehi Khaketla; Heather L Armstrong; Zishan Cui; Paul Sereda; Nathan J Lachowsky; Mark W Hull; Gbolahan Olarewaju; Jody Jollimore; Joshua Edward; Julio S G Montaner; Robert S Hogg; Eric A Roth; David M Moore Journal: AIDS Behav Date: 2018-11
Authors: Angela R Bazzi; Mari-Lynn Drainoni; Dea L Biancarelli; Joshua J Hartman; Matthew J Mimiaga; Kenneth H Mayer; Katie B Biello Journal: BMC Public Health Date: 2019-01-08 Impact factor: 3.295
Authors: David C Knox; Robert Pilarski; Harvinder S Dhunna; Amit Kaushal; Jonathan D Adachi Journal: Can J Infect Dis Med Microbiol Date: 2022-08-30 Impact factor: 2.585
Authors: Carla M Doyle; Joseph Cox; Rachael M Milwid; Raphaël Bitera; Charlotte Lanièce Delaunay; Michel Alary; Gilles Lambert; Cécile Tremblay; Sharmistha Mishra; Mathieu Maheu-Giroux Journal: J Int AIDS Soc Date: 2022-09 Impact factor: 6.707